RAQUEL CASTRO: Open Payments
NPI 1740880913 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,460 in 79 payments from 17 companies in 2025. Trend: 2023 $1,011 · 2024 $1,199 · 2025 $1,460
Food & beverage: $1,460
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $282 |
| ABBVIE INC. | 11 | $223 |
| Novo Nordisk Inc | 13 | $159 |
| Amgen Inc. | 10 | $145 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $131 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $109 |
| PFIZER INC. | 5 | $85 |
| Merck Sharp & Dohme LLC | 3 | $60 |
| Lilly USA, LLC | 3 | $55 |
| Abbott Laboratories | 2 | $38 |
Products named: BYETTA, CAPLYTA, XIFAXAN, VRAYLAR, AIRSUPRA, BREZTRI, QULIPTA, OTEZLA.
Industry payments across AZ — which companies pay providers there.
